Susquehanna Fundamental Investments’s Travere Therapeutics TVTX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-83,857	Closed	-$1.89M	–	870
2023 Q1	$1.89M	Sell	83,857 -5,170	-6%	-$110K	0.04%	387
2022 Q4	$1.87M	Buy	89,027 +36,368	+69%	+$771K	0.03%	505
2022 Q3	$1.3M	Buy	+52,659	New	+$1.36M	0.02%	715
2022 Q1	$1.74M	Buy	67,488 +1,900	+3%	+$50.4K	0.03%	642
2021 Q4	$2.04M	Hold	65,588	–	–	0.05%	419
2021 Q3	$1.59M	Buy	+65,588	New	+$1.21M	0.03%	678

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Susquehanna Fundamental Investments's TVTX Position: Q2 2023 in Review

Susquehanna Fundamental Investments sold out of Travere Therapeutics (TVTX) in Q2 2023, closing a stake of 83,857 shares — an estimated $1.89M sold.

Susquehanna Fundamental Investments first reported a position in TVTX in Q3 2021 and held it in 6 quarters. The position peaked at $2.04M in Q4 2021. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2023.

Susquehanna Fundamental Investments reported no remaining Travere Therapeutics position as of Q2 2023 after selling out during the quarter.
Susquehanna Fundamental Investments sold 83,857 Travere Therapeutics shares in Q2 2023, an estimated $1.89M.
Susquehanna Fundamental Investments first reported a position in Travere Therapeutics in Q3 2021 and held it in 6 quarters.
Susquehanna Fundamental Investments's Travere Therapeutics position peaked at $2.04M in Q4 2021.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2023.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2023, filed 11 Aug 2023.